Thermo Fisher Scientific Expands Viral Vector Manufacturing at Plainville, Massachusetts, Facility
05/12/2020
According to company officials, the $180 million project will more than double the company's commercial viral vector capacity to support increasing demand for the development and manufacture of gene therapies and vaccines.
Construction of the new 290,000-square-foot facility is expected to be completed in 2022. The project will add more than 200 jobs and complement the company's new or recently expanded capacity in Lexington and Cambridge, Massachusetts, and Alachua, Florida.
"The Plainville expansion significantly enhances our 'start here, stay here' strategy, ensuring that customers have an uninterrupted pathway from development through commercialization," said Michel Lagarde, executive vice president of Thermo Fisher Scientific. "Between Plainville and our other expanded sites in the U.S., we're increasing viral vector production to accelerate cell and gene therapy innovation, giving hope to more patients everywhere."
The Plainville site will offer a flexible and scalable configuration of laboratory and production suites co-located with adjacent warehousing and office space. An onsite engineering laboratory will help customers develop turnkey production platforms that enable them to rapidly transition to commercial-scale operations when ready. As with its other viral vector development and manufacturing sites, Thermo Fisher's Plainville site will attract a diverse workforce of scientists, quality control specialists and production teams.
Thermo Fisher strategically selected Plainville to capitalize on its expertise at other Massachusetts locations and draw upon the strong talent pool in the Greater Boston area. The state-of-the-art facility will feature digital connectivity and capabilities that enable operational efficiencies, high quality, data visibility and advanced operator training.
Lagarde added, "The global race to develop new transformative medicines illustrates how important it is for our customers to have access to surge capacity as well as flexibility to adapt and change therapeutic platforms, whether they are developing a new viral vector for a novel therapy or the next life-saving cancer treatment."
Most Read
-
-
What’s Driving Record Industrial Real Estate Demand
Q1 2021
-
2020 Top States for Doing Business Showcase Their Pro-Business Environments
Q3 2020
-
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Q2 2020
-
35th Annual Survey of Corporate Executives Commentary: Change in Site Selection Priorities and Plans Over the Short and Long Term
Q1 2021
-
Pandemic Fuels Data Center Growth
Q1 2021
-
Trends in Office and Industrial Parks
Q4 2020